Center Laboratories, Inc. (4123.TWO)
TWD 41.9
(-1.53%)
TWD 41.9
(-1.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.91 Billion TWD | 46.41% |
| 2022 | 2.67 Billion TWD | -46.51% |
| 2021 | 5 Billion TWD | 75.97% |
| 2020 | 2.84 Billion TWD | -23.26% |
| 2019 | 3.7 Billion TWD | 166.96% |
| 2018 | 1.38 Billion TWD | -82.4% |
| 2017 | 7.88 Billion TWD | 60.97% |
| 2016 | 4.89 Billion TWD | -7.29% |
| 2015 | 5.28 Billion TWD | 386.07% |
| 2014 | 1.08 Billion TWD | 287.3% |
| 2013 | -580.49 Million TWD | -73.35% |
| 2012 | -334.86 Million TWD | 5.33% |
| 2011 | -353.71 Million TWD | 66.54% |
| 2010 | -1.05 Billion TWD | 26.34% |
| 2009 | -1.43 Billion TWD | -20162.37% |
| 2008 | 7.15 Million TWD | -60.37% |
| 2007 | 18.05 Million TWD | -73.66% |
| 2006 | 68.53 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.99 Billion TWD | -23.6% |
| 2024 Q2 | 3.11 Billion TWD | 4.0% |
| 2023 Q1 | 2.49 Billion TWD | -6.86% |
| 2023 Q3 | 4.27 Billion TWD | -9.59% |
| 2023 Q4 | 3.91 Billion TWD | -8.28% |
| 2023 FY | 3.91 Billion TWD | 46.41% |
| 2023 Q2 | 4.72 Billion TWD | 89.58% |
| 2022 Q2 | 372.92 Million TWD | 118.94% |
| 2022 Q4 | 2.67 Billion TWD | 107.43% |
| 2022 FY | 2.67 Billion TWD | -46.51% |
| 2022 Q1 | -1.96 Billion TWD | -139.34% |
| 2022 Q3 | 1.29 Billion TWD | 246.03% |
| 2021 Q4 | 5 Billion TWD | 51.26% |
| 2021 FY | 5 Billion TWD | 75.97% |
| 2021 Q1 | 3.42 Billion TWD | 20.38% |
| 2021 Q2 | 4.22 Billion TWD | 23.5% |
| 2021 Q3 | 3.3 Billion TWD | -21.75% |
| 2020 Q3 | 2.27 Billion TWD | 153.77% |
| 2020 Q4 | 2.84 Billion TWD | 24.78% |
| 2020 Q2 | 897.96 Million TWD | -70.04% |
| 2020 Q1 | 2.99 Billion TWD | -19.12% |
| 2020 FY | 2.84 Billion TWD | -23.26% |
| 2019 FY | 3.7 Billion TWD | 166.96% |
| 2019 Q3 | 3.08 Billion TWD | -20.85% |
| 2019 Q2 | 3.89 Billion TWD | 46.73% |
| 2019 Q1 | 2.65 Billion TWD | 91.42% |
| 2019 Q4 | 3.7 Billion TWD | 20.09% |
| 2018 Q2 | 1.93 Billion TWD | -77.14% |
| 2018 Q1 | 8.44 Billion TWD | 7.08% |
| 2018 FY | 1.38 Billion TWD | -82.4% |
| 2018 Q4 | 1.38 Billion TWD | -50.98% |
| 2018 Q3 | 2.83 Billion TWD | 46.66% |
| 2017 Q3 | 5.86 Billion TWD | -14.37% |
| 2017 Q2 | 6.84 Billion TWD | 17.79% |
| 2017 Q1 | 5.81 Billion TWD | 18.67% |
| 2017 FY | 7.88 Billion TWD | 60.97% |
| 2017 Q4 | 7.88 Billion TWD | 34.48% |
| 2016 Q3 | 5.77 Billion TWD | 1.37% |
| 2016 FY | 4.89 Billion TWD | -7.29% |
| 2016 Q1 | 6.37 Billion TWD | 20.71% |
| 2016 Q2 | 5.69 Billion TWD | -10.73% |
| 2016 Q4 | 4.89 Billion TWD | -15.13% |
| 2015 Q4 | 5.28 Billion TWD | -25.44% |
| 2015 FY | 5.28 Billion TWD | 386.07% |
| 2015 Q3 | 7.08 Billion TWD | 69.94% |
| 2015 Q2 | 4.17 Billion TWD | 201.23% |
| 2015 Q1 | 1.38 Billion TWD | 27.34% |
| 2014 Q1 | -562.12 Million TWD | 3.16% |
| 2014 FY | 1.08 Billion TWD | 287.3% |
| 2014 Q4 | 1.08 Billion TWD | 166.22% |
| 2014 Q3 | -1.64 Billion TWD | -362.55% |
| 2014 Q2 | -354.97 Million TWD | 36.85% |
| 2013 Q2 | -52.31 Million TWD | 5.14% |
| 2013 Q3 | -1.12 Billion TWD | -2042.05% |
| 2013 FY | -580.49 Million TWD | -73.35% |
| 2013 Q4 | -580.49 Million TWD | 48.2% |
| 2013 Q1 | -55.14 Million TWD | 83.53% |
| 2012 Q2 | -336.9 Million TWD | 17.01% |
| 2012 Q4 | -334.86 Million TWD | 24.69% |
| 2012 Q3 | -444.64 Million TWD | -31.98% |
| 2012 Q1 | -405.95 Million TWD | -14.77% |
| 2012 FY | -334.86 Million TWD | 5.33% |
| 2011 Q3 | -550.38 Million TWD | 27.46% |
| 2011 Q1 | -879.93 Million TWD | 16.77% |
| 2011 Q2 | -758.76 Million TWD | 13.77% |
| 2011 Q4 | -353.71 Million TWD | 35.73% |
| 2011 FY | -353.71 Million TWD | 66.54% |
| 2010 FY | -1.05 Billion TWD | 26.34% |
| 2010 Q4 | -1.05 Billion TWD | 0.0% |
| 2009 FY | -1.43 Billion TWD | -20162.37% |
| 2008 FY | 7.15 Million TWD | -60.37% |
| 2007 FY | 18.05 Million TWD | -73.66% |
| 2006 FY | 68.53 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Allied Biotech Corporation | 178.11 Million TWD | -2100.312% |
| GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | -12175.393% |
| Easywell Biomedicals, Inc. | 123.43 Million TWD | -3074.933% |
| TTY Biopharm Company Limited | -705.97 Million TWD | 655.124% |
| Synmosa Biopharma Corporation | 1.52 Billion TWD | -157.611% |
| Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | -26.163% |
| Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | 6909.094% |
| Orient Pharma Co., Ltd. | 633.6 Million TWD | -518.528% |
| InnoPharmax Inc. | -17.85 Million TWD | 22045.582% |
| Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 522.867% |
| Excelsior Biopharma Inc. | -212.51 Million TWD | 1944.142% |
| DV Biomed Co., Ltd. | 160.7 Million TWD | -2338.732% |
| Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 601.527% |
| Handa Pharmaceuticals, Inc. | -653.8 Million TWD | 699.42% |
| UniPharma Co., Ltd. | -68.36 Million TWD | 5832.359% |
| Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | -695.896% |
| Alar Pharmaceuticals Inc. | -738.05 Million TWD | 630.996% |
| Winston Medical Supply Co., Ltd. | -191.81 Million TWD | 2143.19% |
| Mercury Biopharmaceutical Corporation | -1.94 Million TWD | 201593.162% |
| Bioray Biotech Co., Ltd | -27.23 Million TWD | 14491.312% |
| TSH Biopharm Corporation Limited | -568.74 Million TWD | 789.072% |